DOI:
10.1055/s-00000075
Seminars in Respiratory and Critical Care Medicine
LinksClose Window
References
Lundin J, Hagberg H, Repp R. , et al.
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.
Blood 2003;
101 (11) 4267-4272
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.